Ito Masaya, Horikoshi Masaru, Resick Patricia A, Katayanagi Akiko, Miyamae Mitsuhiro, Takagishi Yuriko, Takebayashi Yoshitake, Kanie Ayako, Hirabayashi Naotsugu, Furukawa Toshiaki A
Department of Clinical Dissemination and Training, National Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry, Tokyo, Japan.
National Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry, Tokyo, Japan.
BMJ Open. 2017 Jun 30;7(6):e014292. doi: 10.1136/bmjopen-2016-014292.
Cognitive processing therapy (CPT) is widely regarded as a safe and effective first-line treatment for individuals with post-traumatic stress disorder (PTSD); however, no comparative studies have been conducted to examine the treatment outcomes in an Asian population. The aim of the present trial is to investigate the efficacy of CPT (individual format) as a treatment for PTSD in a population of Japanese patients.
A 16-week, single-centre, assessor-masked, randomised, parallel-group superiority trial has been designed to compare the efficacy of CPT in conjunction with treatment as usual (mostly pharmacotherapy and clinical monitoring) versus treatment as usual alone. The Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) will be our primary outcome measure of the post-traumatic stress symptoms at 17 weeks, whereas the PTSD Checklist for DSM-5 and determination of the operationally defined responder status will be used to assess the secondary outcomes. An estimated sample size of 29 participants in each group will be required to detect an expected effect size of 1.4 (95% CI 0.85 to 1.95).
The institutional review board at the National Center of Neurology and Psychiatry in Japan approved this study. The results of this clinical trial will be presented at conferences and disseminated through publication in a peer-reviewed journal.
UMIN000021670 (registered on 1 April 2016).
认知加工疗法(CPT)被广泛认为是治疗创伤后应激障碍(PTSD)患者的一种安全有效的一线治疗方法;然而,尚未进行比较研究来检验亚洲人群的治疗效果。本试验的目的是调查CPT(个体形式)对日本PTSD患者群体的治疗效果。
设计了一项为期16周的单中心、评估者盲法、随机、平行组优效性试验,以比较CPT联合常规治疗(主要是药物治疗和临床监测)与单纯常规治疗的疗效。《精神疾病诊断与统计手册》第五版(DSM-5)的临床医生管理的PTSD量表将作为我们在17周时创伤后应激症状的主要结局指标,而DSM-5的PTSD检查表和操作性定义的反应者状态的确定将用于评估次要结局。每组估计需要29名参与者的样本量,以检测预期效应量为1.4(95%CI 0.85至1.95)。
日本国立神经精神中心的机构审查委员会批准了本研究。本临床试验的结果将在会议上展示,并通过在同行评审期刊上发表进行传播。
UMIN000021670(于2016年4月1日注册)。